MX2020006040A - Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos. - Google Patents

Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos.

Info

Publication number
MX2020006040A
MX2020006040A MX2020006040A MX2020006040A MX2020006040A MX 2020006040 A MX2020006040 A MX 2020006040A MX 2020006040 A MX2020006040 A MX 2020006040A MX 2020006040 A MX2020006040 A MX 2020006040A MX 2020006040 A MX2020006040 A MX 2020006040A
Authority
MX
Mexico
Prior art keywords
optically active
intermediates
preparation methods
piperidine derivatives
active piperidine
Prior art date
Application number
MX2020006040A
Other languages
English (en)
Inventor
Hyuk Woo Lee
Jae Hong Kweon
Kwang Do Choi
Dong Hyun Ko
Seung Pyeong Heo
Eun Sun Kim
Chae Young Ryu
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of MX2020006040A publication Critical patent/MX2020006040A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18—Carbon
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un procedimiento de preparación de acuerdo con la presente invención hace posible producir industrialmente grandes cantidades de 3-metil-4-oxopiperidin-1- carboxilato de terc-butilo ópticamente puro de alta pureza con gran rendimiento mediante el uso de reactivos y disolventes disponibles comercialmente. Además, el uso de intermedios novedosos de acuerdo con la presente invención hace posible producir 3-metil-4-oxopiperidin-1-carboxilato de terc-butilo ópticamente activo de alta pureza con gran rendimiento.
MX2020006040A 2017-12-11 2018-12-07 Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos. MX2020006040A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170169227A KR102037494B1 (ko) 2017-12-11 2017-12-11 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
PCT/KR2018/015559 WO2019117550A1 (en) 2017-12-11 2018-12-07 Intermediates for optically active piperidine derivatives and preparation methods thereof

Publications (1)

Publication Number Publication Date
MX2020006040A true MX2020006040A (es) 2020-10-12

Family

ID=66819511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006040A MX2020006040A (es) 2017-12-11 2018-12-07 Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos.

Country Status (12)

Country Link
US (2) US11254641B2 (es)
EP (1) EP3724162B1 (es)
JP (1) JP6966656B2 (es)
KR (1) KR102037494B1 (es)
CN (1) CN111587240B (es)
AU (1) AU2018385820B2 (es)
BR (1) BR112020011630A2 (es)
CA (1) CA3085427C (es)
ES (1) ES2960509T3 (es)
MX (1) MX2020006040A (es)
RU (1) RU2752477C1 (es)
WO (1) WO2019117550A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
CN114213316B (zh) * 2021-12-29 2024-04-02 苏州诚和医药化学有限公司 一种旋光哌啶衍生物的中间体的生产工艺
CN115010652A (zh) * 2022-07-14 2022-09-06 苏州诚和医药化学有限公司 一种哌啶类衍生物中间体的合成工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU606310A1 (ru) * 1976-10-29 1984-05-23 Московский государственный университет им.М.В.Ломоносова Способ получени (+) и (-)-формы оптически активного транс-2,5-диметилпиперидона-4
FR2717803B1 (fr) * 1994-03-25 1996-06-21 Meram Lab Dérivés substitués d'hétérocycles azotés et leurs isomères, actifs sur le système nerveux central, procédé d'obtention et compositions pharmaceutiques les contenant.
DE60006825T2 (de) 1999-07-29 2004-08-12 Eli Lilly And Co., Indianapolis Serotonerge benzofurane
CA2502178A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Heteroarylpiperidine modulators of chemokine receptor activity
AU2003303483A1 (en) 2002-12-23 2004-07-22 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
US7608629B2 (en) * 2003-04-18 2009-10-27 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
ATE420881T1 (de) 2003-09-17 2009-01-15 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
US20120041225A1 (en) 2006-02-03 2012-02-16 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
WO2009015164A2 (en) * 2007-07-24 2009-01-29 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2009106534A1 (en) 2008-02-26 2009-09-03 H. Lundbeck A/S Novel heterocyclic carboxamides as m1 agonists
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
KR101146009B1 (ko) * 2009-10-01 2012-05-15 동인화학 주식회사 광학 분리에 의한 활성 피페리딘 화합물의 제조방법
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
CN103917540B (zh) 2011-08-10 2016-03-16 爱尔兰詹森科学公司 抗细菌的哌啶基取代的3，4-二氢-1h-[1，8]萘啶酮
WO2013116491A1 (en) * 2012-02-01 2013-08-08 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using them
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
BR112015002931B1 (pt) 2012-08-10 2019-10-29 Janssen Sciences Ireland Uc compostos antibacterianos, seu uso, composição farmacêutica que os compreende e processo de preparação destes
US10385036B2 (en) 2015-01-30 2019-08-20 Pfizer Inc. Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
CA2975060C (en) 2015-01-30 2019-09-03 Pfizer Inc. Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법

Also Published As

Publication number Publication date
KR102037494B1 (ko) 2019-10-28
WO2019117550A1 (en) 2019-06-20
BR112020011630A2 (pt) 2020-11-17
RU2752477C1 (ru) 2021-07-28
KR20190068946A (ko) 2019-06-19
ES2960509T3 (es) 2024-03-05
EP3724162A4 (en) 2021-08-11
CA3085427A1 (en) 2019-06-20
CN111587240B (zh) 2023-09-01
AU2018385820B2 (en) 2021-08-12
EP3724162C0 (en) 2023-10-11
JP2021505682A (ja) 2021-02-18
US20220127230A1 (en) 2022-04-28
EP3724162A1 (en) 2020-10-21
US11780810B2 (en) 2023-10-10
CA3085427C (en) 2023-03-14
US20210107873A1 (en) 2021-04-15
US11254641B2 (en) 2022-02-22
EP3724162B1 (en) 2023-10-11
JP6966656B2 (ja) 2021-11-17
CN111587240A (zh) 2020-08-25
AU2018385820A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
MX2020006040A (es) Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos.
MY172391A (en) Processes for preparing dihydropyrimidine derivatives and intermediates thereof
SG10201809312QA (en) Nucleic acid synthesis techniques
JOP20160185B1 (ar) طريقة لتحضير (4s)-4-(4- سيانو-2- ميثوكسي فنيل)-5- إيثوكسي-8،2-داي ميثيل-4،1-داي هيدرو-6،1- نافثيريدين-3- كربوكساميد واسترجاع (4s)-4-(4- سيانو-2- ميثوكسي فنيل)-5- إيثوكسي-8،2- داي ميثيل-4،1- داي هيدرو-6،1- نافثيريدين-3- كربوكساميد بواسطة طرق كهروكيميائية
PH12019502386A1 (en) Process for preparing s-containing pyrimidinium compounds
TW201612319A (en) Microorganism producing O-phosphoserine and a method for producing O-phosphoserine or L-cysteine using the same
WO2018029711A3 (en) Process for the preparation of venetoclax
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
EA201691754A1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
MX2019001465A (es) Metodo de produccion de cetoenoles ciclicos sustituidos con espirocetales.
PH12018501642A1 (en) Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof
WO2016012445A3 (en) Process for the purification of poliovirus from cell cultures
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
MX2018004009A (es) Proceso para la recuperacion de una mezcla que comprende un derivado de acido (tio) fosforico.
WO2017093866A3 (en) An improved process for the preparation of indigo carmine
MX2017007931A (es) Nuevas formas cristalinas de la sal de monosodio del foramsulfuron.
WO2016084100A3 (en) Novel and efficient method for large scale synthesis of romidepsin
NZ727773A (en) Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy- cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs
WO2016079757A3 (en) NOVEL PROCESSES FOR THE PREPARATION OF SUBSTITUTED 5-HYDROXYMETHYL-OXAZOLIDINE-2-ONE
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
MX349985B (es) Procedimiento de preparación de ésteres de fenilacetil aminoácido espirocíclicos con sustitución cis-alcoxi y derivados de 1h-pirrolidin-2,4-diona espirocicíclicos con sustitución cis-alcoxi.
IN2014CH01392A (es)
WO2015104602A3 (en) A process for the preparation of anagliptin and its intermediates thereof
IN2014MU00486A (es)
WO2017098520A8 (en) PROCESS FOR THE PREPARATION OF LABETALOL CHLORHYDRATE